Galera Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GRTX research report →
Price Chart
About the company
Galera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation and commercialization of therapies aimed at revolutionizing cancer radiotherapy. Its lead investigational drug, avasopasem manganese (GC4419), functions as a small molecule superoxide dismutase mimetic.
- CEO
- J. Mel Sorensen
- IPO
- 2019
- Employees
- 3
- HQ
- Malvern, PA, US
Get TickerSpark's AI analysis on GRTX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $3.56B
- P/E
- 0.06
- PEG
- 0.00
- P/S
- 0.00
- P/B
- 1.68
- EV/EBITDA
- -625.67
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -210.64%
- ROIC
- -114.15%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+100.0%
- Op Income
- $-6,042,000
- Net Income
- $149.05M+886.2%
- EPS
- $302.00+531.4%
- OCF Growth
- +50.2%
- FCF Growth
- +50.2%
- 52W High
- $30.00
- 52W Low
- $0.09
- 50D MA
- $18.46
- 200D MA
- $10.26
- Beta
- 2.60
- RSI (14)
- 60
- Avg Volume
- 512
No earnings-call transcripts are available for GRTX yet.
- Free Float
- 0.2%
- Shares Outstanding
- 207.76M
- Float Shares
- 493.49K
of shares held by institutions
1 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Tekla Capital Management LLC | 898.37K | 0 |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 3, 26 | Sorensen Mel | sell | 975 |
| Aug 3, 26 | Sorensen Mel | sell | 30,000 |
| Aug 3, 26 | LOKAY KEVIN G | sell | 240 |
| May 15, 26 | CHANG NANCY T | other | 661,309 |
| Aug 3, 26 | CHANG NANCY T | sell | 47,434 |
| May 15, 26 | CHANG NANCY T | other | 661.309 |
| Aug 3, 26 | CHANG NANCY T | sell | 480 |
| Aug 3, 26 | Alleva Lawrence M | sell | 40 |
| Aug 3, 26 | Alleva Lawrence M | sell | 240 |
| Aug 3, 26 | Sussman Joel F. | sell | 10,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our GRTX coverage
Recent articles, reports, and earnings notes.
No research on GRTX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate GRTX report →Obsidian Therapeutics Completes Closing of Transaction with Galera Therapeutics and Previously Announced Private Placement of $350 Million
businesswire.com · Aug 3
Galera Therapeutics (NASDAQ:GRTX) vs. Eagle Pharmaceuticals (NASDAQ:EGRX) Head to Head Review
defenseworld.net · Jul 17
GRTX Stock Alert: Halper Sadeh LLC is Investigating Whether Galera Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders
businesswire.com · Apr 14
Galera Therapeutics and Obsidian Therapeutics Announce Merger Agreement and $350 Million Concurrent Private Placement
globenewswire.com · Apr 14
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Galera Therapeutics, Inc. (OTCMKTS: GRTX)
globenewswire.com · Apr 14
Obsidian Therapeutics and Galera Therapeutics Announce Merger Agreement and $350 Million Concurrent Private Placement
businesswire.com · Apr 14
Athersys (NASDAQ:ATHX) and Galera Therapeutics (NASDAQ:GRTX) Critical Review
defenseworld.net · Feb 16
Critical Review: Galera Therapeutics (NASDAQ:GRTX) versus China Pharma (NYSE:CPHI)
defenseworld.net · Dec 27
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.